The granulocyte-macrophage colony-stimulating factor receptor: Linking its structure to cell signaling and its role in disease

Blood

Volumn 114, Issue 7, 2009, Pages 1289-1298

  Hercus, Timothy R ^a   Thomas, Daniel ^a   Guthridge, Mark A ^a   Ekert, Paul G ^b   King Scott, Jack ^c   Parker, Michael W ^c   Lopez, Angel F ^a  

^a University of Adelaide   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 5 RECEPTOR; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLERGIC DISEASE; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CRYSTAL STRUCTURE; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; LUNG FUNCTION; MACROPHAGE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; HYPERSENSITIVITY; INFLAMMATION; LUNG; METABOLISM; MYELOID LEUKEMIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ACUTE DISEASE; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DISEASE; HOMEOSTASIS; HUMANS; HYPERSENSITIVITY; INFLAMMATION; LEUKEMIA, MYELOID; LUNG; MACROPHAGES; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349336496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-164004     Document Type: Review

References (144)

1. Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485-491.
2. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255-258.
3. Dirksen U, Hattenhorst U, Schneider P, et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common β chain in children with acute myeloid leukemia associated with respiratory failure. Blood. 1998;92:1097-1103.
4. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colonystimulating factor in pulmonary homeostasis. Science. 1994;264:713-716.
5. Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089-1098.
6. Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRα gene in the X chromosome pseudoautosomal region 1. J Exp Med. 2008;205:2711-2716.
7. Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med. 2008;205:2703-2710.
8. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte-macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91:5592-5596.
9. Robb L, Drinkwater CC, Metcalf D, et al. Hematopoietic and lung abnormalities in mice with a null mutation of the common β subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci U S A. 1995;92:9565-9569.
10. Nakata K, Akagawa KS, Fukayama M, et al. Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro. J Immunol. 1991;147:1266-1272.
11. Shibasaki T, Katayama N, Ohishi K, et al. IL-3 can not replace GM-CSF in inducing human monocytes to differentiate into Langerhans cells. Int J Oncol. 2007;30:549-555.
12. Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol. 2005;25:405-428.
13. Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors. 2004;22:225-231.
14. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia. 2008;22:1335-1342.
15. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zucherman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925-929.
16. Kochetkova M, Iversen PO, Lopez AF, Shannon MF. Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells. J Clin Invest. 1997;99:3000-3008.
17. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195.
18. Kim A, Morgan K, Hasz DE, et al. Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 2007;109:1687-1691.
19. Ramshaw HS, Bardy PG, Lee M, Lopez AF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol. 2002;30:1124-1131.
20. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214-4222.
21. Janssen JW, Steenvoorden AC, Lyons J, et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci U S A. 1987;84:9228-9232.
22. Guthridge MA, Powell JA, Barry EF, et al. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J. 2006;25:479-489.
23. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor β (c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res. 1996;56:3426-3430.
24. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
25. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533-544.
26. Niki Y, Takaishi H, Takito J, et al. Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1α transgenic mice due to GM-CSF overproduction. J Immunol. 2007;179:639-646.
27. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis. 1997;56:364-368.
28. Campbell IK, Rich MJ, Bischof RJ, et al. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. 1998;161:3639-3644.
29. Walker F, Burgess AW. Specific binding of radio-iodinated granulocyte-macrophage colony-stimulating factor to hemopoietic cells. EMBO J 1985;4:933-939.
30. Park LS, Friend D, Gillis S, Urdal DL. Characterization of the cell surface receptor for human granulocyte/macrophage colony-stimulating factor. J Exp Med. 1986;164:251-262.
31. Gearing DP, King JA, Gough NM, Nicola NA. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J. 1989;8:3667-3676.
32. Hayashida K, Kitamura T, Gorman DM, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A. 1990;87:9655-9659.
33. Baldwin G, Gasson J, Kaufman S, et al. Nonhematopoietic tumor cells express functional GMC-SF receptors. Blood. 1989;73:1033-1037.
34. Dedhar S, Gaboury L, Galloway P, Eaves C. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci U S A. 1988;85:9253-9257.
35. Bussolino F, Wang JM, Defilippi P, et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature. 1989;337:471-473.
36. Rivas CI, Vera JC, Delgado-Lopez F, et al. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer. Blood. 1998;91:1037-1043.
37. McCormack MP, Gonda TJ. Novel murine myeloid cell lines that exhibit a differentiation switch in response to IL-3 or GM-CSF, or to different constitutively active mutants of the GM-CSF receptor β subunit. Blood. 2000;95:120-127.
38. Didichenko SA, Spiegl N, Brunner T, Dahinden CA. IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils. Blood. 2008;112:3949-3958.
39. Hansen G, Hercus TR, McClure BJ, et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor assembly. Cell. 2008;134:496-507.
40. Kanakura Y, Cannistra SA, Brown CB, et al. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991;77:1033-1043.
41. Dempsey PJ, Layton JE, Duhrsen U, et al. Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro. Hybridoma. 1990;9:545-558.
42. Sun Q, Jones K, McClure B, et al. Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Blood. 1999;94:1943-1951.
43. Hercus TR, Cambareri B, Dottore M, et al. Identification of residues in the first and fourth helices of human granulocyte-macrophage colony stimulating factor involved in binding to the α- and β-chains of the receptor. Blood. 1994;83:3500-3508.
44. 21 of GM-CSF. EMBO J. 1994;13:5176-5185.
45. Woodcock JM, Bagley CJ, Zacharakis B, Lopez AF. A single tyrosine residue in the membrane-proximal domain of the GM-CSF, IL-3 and IL-5 receptor common β chain is necessary and sufficient for high affinity binding and signalling by all three ligands. J Biol Chem. 1996;271:25999-26006.
46. Rajotte D, Cadieux C, Haman A, et al. Crucial role of the residue R280 at the F′-G′ loop of the human granulocyte/macrophage colony-stimulating factor receptor α chain for ligand recognition. J Exp Med. 1997;185:1939-1950.
47. Haman A, Cadieux C, Wilkes B, et al. Molecular determinants of the granulocyte-macrophage colony-stimulating factor receptor complex assembly. J Biol Chem. 1999;274:34155-34163.
48. Shanafelt AB, Johnson KE, Kastelein RA. Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J Biol Chem. 1991;266:13804-13810.
49. Lock P, Metcalf D, Nicola NA. Histidine-367 of the human common β chain of the receptor is critical for high-affinity binding of human granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci U S A. 1994;91:252-256.
50. Rozwarski DA, Diederichs K, Hecht R, Boone T, Karplus PA. Refined crystal structure and mutagenesis of human granulocyte-macrophage colony-stimulating factor. Proteins. 1996;26:304-313.
51. Rossjohn J, McKinstry WJ, Woodcock JM, et al. Structure of the activation domain of the GMC-SF/IL-3/IL-5 receptor common β chain bound to an antagonist. Blood. 2000;95:2491-2498.
52. Mulhern TD, Lopez AF, D'Andrea RJ, et al. The solution structure of the cytokine-binding domain of the common β-chain of the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. J Mol Biol. 2000;297:989-1001.
53. Carr PD, Gustin SE, Church AP, et al. Structure of the complete extracellular domain of the common β subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell. 2001;104:291-300.
54. McClure BJ, Hercus TR, Cambareri BA, et al. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood. 2003;101:1308-1315.
55. Hansen G, Hercus TR, Xu Y, et al. Crystallization and preliminary X-ray diffraction analysis of the ternary human GM-CSF receptor complex. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008;64:711-714.
56. Carr PD, Conlan F, Ford S, Ollis DL, Young IG. An improved resolution structure of the human β common receptor involved in IL-3, IL-5 and GM-CSF signalling which gives better definition of the high-affinity binding epitope. Acta Crystallographr Sect F Struct Biol Cryst Commun. 2006;62:509-513.
57. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306-312.
58. Wells JA, De Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 1996;65:609-634.
59. Lopez AF, Shannon MF, Hercus T, et al. Residue 21 of human granulocyte-macrophage colony-stimulating factor is critical for biological activity and for high but not low affinity binding. EMBO J. 1992;11:909-916.
60. Hercus TR, Bagley CJ, Cambareri B, et al. Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc Natl Acad Sci U S A. 1994;91:5838-5842.
61. Murphy JM, Ford SC, Wiedemann UM, et al. A novel functional epitope formed by domains 1 and 4 of the human common β-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5. J Biol Chem. 2003;278:10572-10577.
62. Barry SC, Bagley CJ, Phillips J, et al. Two contiguous residues in human interleukin-3, Asp21 and Glu22, selectively interact with the α- and β-chains of its receptor and participate in function. J Biol Chem. 1994;269:8488-8492.
63. Tavernier J, Tuypens T, Verhee A, et al. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci U S A. 1995;92:5194-5198.
64. Woodcock JM, McClure B, Stomski FC, et al. The human granulocyte- macrophage colony-stimulating factor (GM-CSF) receptor exists as a preformed receptor complex that can be activated by GM-CSF interleukin-3, or interleukin-5. Blood. 1997;90:3005-3017.
65. Wang X, Lupardus P, La Porte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27:29-60.
66. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell. 2003;12:577-589.
67. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors. Science. 2005;310:1159-1163.
68. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006;103:2788-2793.
69. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259-272.
70. Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/receptor α chain complex reveals a mosaic binding interface. Cell. 1999;97:271-281.
71. Skiniotis G, Boulanger MJ, Garcia KC, Walz T. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol. 2005;12:545-551.
72. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
73. Sakamaki K, Miyajima I, Kitamura T, Miyajima A. Critical cytoplasmic domains of the common β subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation. EMBO J. 1992;11:3541-3549.
74. Muto A, Watanabe S, Itoh T, et al. Roles of the cytoplasmic domains of the α and β subunits of human granulocyte-macrophage colony-stimulating factor receptor. J Allergy Clin Immunol. 1995;96:1100-1114.
75. Brizzi MF, Zini MG, Aronica MG, et al. Convergence of signaling by interleukin-3, granulocyte-macrophage colony-stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase. J Biol Chem. 1994;269:31680-31684.
76. c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane proximal region. Mol Cell Biol. 1994;14:4335-4341.
77. Lilly MB, Zemskova M, Frankel AE, Salo J, Kraft AS. Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor α subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001;97:1662-1670.
78. Lia F, Rajotte D, Clark SC, Hoang T. A dominant negative granulocyte-macrophage colony-stimuating factor receptor α chain reveals the multimeric structure of the receptor complex. J Biol Chem. 1996;271:28287-28293.
79. Chen J, Olsen J, Ford S, et al. A new isoform of interleukin-3 receptor α with novel differentiation activity and high affinity binding mode. J Biol Chem. 2009;284:5763-5773.
80. Guthridge MA, Stomski FC, Thomas D, et al. Mechanism of activation of the GM-CSF, IL-3 and IL-5 family of receptors. Stem Cells. 1998;16:301-313.
81. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179-185.
82. Guthridge MA, Stomski FC, Barry EF, et al. Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival. Mol Cell. 2000;6:99-108.
83. Guthridge MA, Barry EF, Felquer FA, et al. The phosphoserine-585- dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-κB and induction of bcl-2. Blood. 2004;103:820-827.
84. Begley CG, Lopez AF, Nicola NA, et al. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood. 1986;68:162-166.
85. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343:76-79.
86. Olayioye MA, Guthridge MA, Stomski FC, et al. Threonine 391 phosphorylation of the human prolactin receptor mediates a novel interaction with 14-3-3 proteins. J Biol Chem. 2003;278:32929-32935.
87. Guthridge MA, Lopez AF. Phosphotyrosine/phosphoserine binary switches: a new paradigm for the regulation of PI3K signalling and growth factor pleiotropy? Biochem Soc Trans. 2007;35:250-252.
88. Lonic A, Barry EF, Quach C, et al. Fibroblast growth factor receptor 2 phosphorylation on serine 779 couples to 14-3-3 and regulates cell survival and proliferation. Mol Cell Biol. 2008;28:3372-3385.
89. Ramshaw HS, Guthridge MA, Stomski FC, et al. The Shc binding site of the βc subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood. 2007;110:3582-3590.
90. Barry EF, Felquer FA, Powell JA, et al. 14-3-3: SHC scaffolds integrate phoshoserine and phosphotyrosine signaling to regulate PI 3-kinase activation and cell survival. J Biol Chem. 2009;284:12080-12090.
91. Chao J-R, Wang T-F, Lee S-F, et al. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling pathway and is one component of the GM-CSF viability response. Mol Biol Cell. 1998;18:4883-4898.
92. Lindsten T, Thompson CB. Cell death in the absence of Bax and Bak. Cell Death Differ. 2006;13:1272-1276.
93. Ekert PG, Jabbour AM, Manoharan A, et al. Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma. Blood. 2006;108:1461-1468.
94. Fletcher JI, Huang DC. BH3-only proteins: orchestrating cell death. Cell Death Differ. 2006;13:1268-1271.
95. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286:1735-1738.
96. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cells. 2003;4:321-328.
97. Ekoff M, Kaufmann T, Engstrom M, et al. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood. 2007;110:3209-3217.
98. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not bcl-xL. Cell. 1996;87:619-628.
99. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of Bad through the protein kinase Akt. Science. 1997;278:687-689.
100. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ. 2005;12:1008-1014.
101. Sunters A, Fernandez de MS, Stahl M, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem. 2003;278:49795-49805.
102. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006;203:1657-1663.
103. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;21:749-760.
104. Zhao Y, Altman BJ, Coloff JL, et al. Glycogen synthase kinase 3α and 3β mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 2007;27:4328-4339.
105. Bernard F, Thomas C, Emile JF, et al. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood. 2002;99:2615-2616.
106. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998;92:4279-4286.
107. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
108. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
109. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukocyte Biol. 2006;80:705-713.
110. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3:293-298.
111. McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194:873-882.
112. Marusic S, Miyashiro JS, Douhan J, III, et al. Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neurosci Lett. 2002;332:185-189.
113. Ponomarev ED, Shriver LP, Maresz K, et al. GMCSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol. 2007;178:39-48.
114. Kitching AR, Ru Huang X, Turner AL, et al. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol. 2002;13:350-358.
115. Timoshanko JR, Kitching AR, Semple TJ, Holdsworth SR, Tipping PG. Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis. J Am Soc Nephrol. 2005;16:2646-2656.
116. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor α chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
117. Muñoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261-1269.
118. Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol. 2004;72:89-106.
119. Lock RB, Jin L, Lee EM, et al. CD123 (IL-3 receptor α chain) neutralization by a monoclonal antibody selectively eliminates human acute myeloid leukemic stem cells. Blood (ASH Annual Meeting Abstracts). 2007;110:161.
120. Roberts AW, He S, Bradstock KF, et al. A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. Blood (ASH Annual Meeting Abstracts). 2008;112:2956.
121. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-1228.
122. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-993.
123. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-984.
124. Yamashita N, Tashimo H, Ishida H, et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol. 2002;219:92-97.
125. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/Macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFκB and AP-1 in vivo. J Biol Chem. 2002;277:42808-42814.
126. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralizing granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther. 2006;112:106-115.
127. Asquith KL, Ramshaw HS, Hansbro PM, et al. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol. 2008;180:1199-1206.
128. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukemias associated with Down's syndrome. Lancet. 2008;372:1484-1492.
129. Wernig G, Gonneville JR, Crowley BJ, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008;111:3751-3759.
130. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-18967.
131. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem. 2008;283:5258-5266.
132. Dai CH, Krantz SB, Dessypris EN, et al. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 1992;80:891-899.
133. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood. 2000;95:639-645.
134. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
135. Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene. 2008;27:3194-3200.
136. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by upregulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 2008;111:379-382.
137. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005;106:1063-1066.
138. Tamburini J, Elie C, Bardet V, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 2007;110:1025-1028.
139. Jones D. Pathways to cancer therapy. Nat Rev Drug Discov. 2008;7:875-876.
140. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-1443.
141. Scott CL, Schuler M, Marsden VS, et al. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol. 2004;164:89-96.
142. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A. 2004;101:6164-6169.
143. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16:360-367.
144. DeLano WL. DeLano Scientific (San Carlos, CA). http://pymol.sourceforge. net/. 2002.